

Zydus Cadila to market Benazepril in the US

Ahmedabad, 26 May 2008

Zydus Cadila has received an approval from the USFDA to market Benazepril Tablets 5, 10, 20 and 40 mg. The drug falls in the cardiovascular segment and the combined sales of all the strengths as per NDC was estimated at USD 301 million in 2007.

This marks the 38th ANDA approval for the group. So far, the group has filed 78 ANDAs and 59 DMFs.
